Benjamin Sredni - Publications

Affiliations: 
Faculty of Life Sciences Bar-Ilan University, Jerusalem, Jerusalem District, Israel 

90 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Yossipof TE, Bazak ZR, Kenigsbuch-Sredni D, Caspi RR, Kalechman Y, Sredni B. Tellurium Compounds Prevent and Reverse Type-1 Diabetes in NOD Mice by Modulating α4β7 Integrin Activity, IL-1β, and T Regulatory Cells. Frontiers in Immunology. 10: 979. PMID 31191514 DOI: 10.3389/Fimmu.2019.00979  0.361
2019 Bing SJ, Shemesh I, Chong WP, Horai R, Jittayasothorn Y, Silver PB, Sredni B, Caspi RR. AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells. Journal of Autoimmunity. PMID 30853312 DOI: 10.1016/J.Jaut.2019.02.006  0.373
2017 Hachmo Y, Kalechman Y, Skornick I, Gafter U, Caspi RR, Sredni B. The Small Tellurium Compound AS101 Ameliorates Rat Crescentic Glomerulonephritis: Association with Inhibition of Macrophage Caspase-1 Activity Very Late Antigen-4 Inactivation. Frontiers in Immunology. 8: 240. PMID 28326083 DOI: 10.3389/Fimmu.2017.00240  0.319
2016 Silberman A, Kalechman Y, Hirsch S, Erlich Z, Sredni B, Albeck A. The Anticancer Activity of Organotelluranes: Potential Role in Integrin Inactivation. Chembiochem : a European Journal of Chemical Biology. 17: 918-27. PMID 26991356 DOI: 10.1002/Cbic.201500614  0.315
2015 Danoch H, Kalechman Y, Albeck M, Longo DL, Sredni B. Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis. Molecular Cancer Research : McR. 13: 411-22. PMID 25351768 DOI: 10.1158/1541-7786.Mcr-14-0459  0.406
2014 Shemesh II, Rozen-Zvi B, Kalechman Y, Gafter U, Sredni B. AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway. Plos One. 9: e114287. PMID 25474550 DOI: 10.1371/Journal.Pone.0114287  0.329
2014 Halpert G, Sredni B. The effect of the novel tellurium compound AS101 on autoimmune diseases. Autoimmunity Reviews. 13: 1230-5. PMID 25153485 DOI: 10.1016/J.Autrev.2014.08.003  0.39
2014 Xie L, Chen J, McMickle A, Awar N, Nady S, Sredni B, Drew PD, Yu S. The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 273: 31-41. PMID 24975323 DOI: 10.1016/J.Jneuroim.2014.05.015  0.41
2014 Halpert G, Eitan T, Voronov E, Apte RN, Rath-Wolfson L, Albeck M, Kalechman Y, Sredni B. Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis. The Journal of Biological Chemistry. 289: 17215-27. PMID 24764299 DOI: 10.1074/Jbc.M113.536664  0.385
2014 Layani-Bazar A, Skornick I, Berrebi A, Pauker MH, Noy E, Silberman A, Albeck M, Longo DL, Kalechman Y, Sredni B. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Research. 74: 3092-103. PMID 24699624 DOI: 10.1158/0008-5472.Can-13-2159  0.338
2014 Lee JH, Halperin-Sheinfeld M, Baatar D, Mughal MR, Tae HJ, Kim JW, Carter A, Lustig A, Snir O, Lavie G, Okun E, Mattson MP, Sredni B, Taub DD. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS. Neuromolecular Medicine. 16: 292-307. PMID 24272426 DOI: 10.1007/S12017-013-8277-3  0.351
2013 Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Science Translational Medicine. 5: 185ra62. PMID 23677591 DOI: 10.1126/Scitranslmed.3005402  0.335
2013 Ling D, Liu B, Jawad S, Thompson IA, Nagineni CN, Dailey J, Chien J, Sredni B, Nussenblatt RB. The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium. The British Journal of Ophthalmology. 97: 934-8. PMID 23624272 DOI: 10.1136/Bjophthalmol-2012-301962  0.397
2013 Naor Y, Hayun M, Sredni B, Don J. Multiple signal transduction pathways are involved in G2/M growth arrest and apoptosis induced by the immunomodulator AS101 in multiple myeloma. Leukemia & Lymphoma. 54: 160-6. PMID 22712839 DOI: 10.3109/10428194.2012.704032  0.31
2012 Sredni B. Immunomodulating tellurium compounds as anti-cancer agents. Seminars in Cancer Biology. 22: 60-9. PMID 22202556 DOI: 10.1016/J.Semcancer.2011.12.003  0.335
2012 Tartakovsky B, Sredni B, Zigman-Hoffman E, Senyor G, Naparstek E. A Peptide of CD14 Protects Human Lymphocytes from Gliotoxin-Induced Apoptosis International Journal of Peptide Research and Therapeutics. 18: 249-258. DOI: 10.1007/S10989-012-9298-8  0.323
2009 Brodsky M, Hirsh S, Albeck M, Sredni B. Resolution of inflammation-related apoptotic processes by the synthetic tellurium compound, AS101 following liver injury. Journal of Hepatology. 51: 491-503. PMID 19595469 DOI: 10.1016/J.Jhep.2009.04.024  0.338
2009 Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N, Sredni B. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model. Experimental Hematology. 37: 593-603. PMID 19375650 DOI: 10.1016/J.Exphem.2009.01.006  0.305
2009 Hayun R, Okun E, Berrebi A, Shvidel L, Bassous L, Sredni B, Nir U. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 50: 625-32. PMID 19373661 DOI: 10.1080/10428190902789181  0.334
2009 Sinuani I, Weissgarten J, Beberashvili I, Rapoport MJ, Sandbank J, Feldman L, Albeck M, Averbukh Z, Sredni B. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 24: 2328-38. PMID 19321762 DOI: 10.1093/Ndt/Gfn742  0.343
2008 Frei GM, Kremer M, Hanschmann KM, Krause S, Albeck M, Sredni B, Schnierle BS. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101. The British Journal of Dermatology. 158: 578-86. PMID 18241275 DOI: 10.1111/J.1365-2133.2007.08414.X  0.359
2008 Eisenstein Z, Engelsman E, Weiss M, Kalechman Y, Sredni B. Modulation of the IL-2 production defect in vitro in Graves' disease. Clinical and Experimental Immunology. 96: 323-328. PMID 8187341 DOI: 10.1111/J.1365-2249.1994.Tb06561.X  0.382
2008 Blank M, Sredni B, Albeck M, Mozes E, Shoenfeld Y. The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody. Clinical and Experimental Immunology. 79: 443-447. PMID 2317948 DOI: 10.1111/J.1365-2249.1990.Tb08109.X  0.381
2008 Naparstek E, Sredni B, Zigman E, Senyor G, Tartakovsky B. Soluble CD14 Protects Human Lymphocytes from Apoptosis Blood. 112: 2566-2566. DOI: 10.1182/Blood.V112.11.2566.2566  0.313
2007 Frei GM, Lebenthal I, Albeck M, Albeck A, Sredni B. Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake. Biochemical Pharmacology. 74: 712-22. PMID 17632085 DOI: 10.1016/J.Bcp.2007.05.011  0.345
2007 Brodsky M, Yosef S, Galit R, Albeck M, Longo DL, Albeck A, Sredni B. The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 27: 453-62. PMID 17572009 DOI: 10.1089/Jir.2007.0168  0.373
2007 Okun E, Dikshtein Y, Carmely A, Saida H, Frei G, Sela BA, Varshavsky L, Ofir A, Levy E, Albeck M, Sredni B. The organotellurium compound ammonium trichloro(dioxoethylene-o,o')tellurate reacts with homocysteine to form homocystine and decreases homocysteine levels in hyperhomocysteinemic mice. The Febs Journal. 274: 3159-70. PMID 17521335 DOI: 10.1111/J.1742-4658.2007.05842.X  0.317
2007 Hayun M, Okun E, Hayun R, Gafter U, Albeck M, Longo DL, Sredni B. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia. 21: 1504-1513. PMID 17508000 DOI: 10.1038/Sj.Leu.2404746  0.304
2007 Hayun R, Shpungin S, Malovani H, Albeck M, Okun E, Nir U, Sredni B. Novel involvement of the immunomodulator AS101 in IL-10 signaling, via the tyrosine kinase Fer. Annals of the New York Academy of Sciences. 1095: 240-50. PMID 17404037 DOI: 10.1196/Annals.1397.028  0.369
2006 Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J, Haran-Ghera N, Sredni B. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway. Biochemical Pharmacology. 72: 1423-31. PMID 16889755 DOI: 10.1016/J.Bcp.2006.06.015  0.357
2006 Sinuani I, Averbukh Z, Gitelman I, Rapoport MJ, Sandbank J, Albeck M, Sredni B, Weissgarten J. Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: effect of the immunomodulator AS101 on this process. American Journal of Physiology. Renal Physiology. 291: F384-94. PMID 16571592 DOI: 10.1152/Ajprenal.00418.2005  0.358
2006 Okun E, Saida H, Albeck M, Sredni B, Avtalion RR. Upregulation of carp GDNF mRNA by the immunomodulator AS101. Developmental and Comparative Immunology. 30: 441-6. PMID 16169589 DOI: 10.1016/J.Dci.2005.07.002  0.378
2005 Shohat M, Mimouni D, Ben-Amitai D, Sredni B, Sredni D, Shohat B, David M. In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101. Clinical and Experimental Dermatology. 30: 432-434. PMID 15953089 DOI: 10.1111/J.1365-2230.2005.01817.X  0.338
2004 Gafter-Gvili A, Kalechman Y, Sredni B, Gal R, Gafter U. Cyclosporin A-induced hair growth in mice is associated with inhibition of hair follicle regression Archives of Dermatological Research. 296: 265-269. PMID 15503089 DOI: 10.1007/S00403-004-0516-X  0.315
2004 Kalechman Y, Gafter U, Weinstein T, Chagnac A, Freidkin I, Tobar A, Albeck M, Sredni B. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3. The Journal of Biological Chemistry. 279: 24724-32. PMID 15001575 DOI: 10.1074/Jbc.M312006200  0.389
2004 Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, Ram Z, Orenstein A, Kershenovich A, Michowiz S, Cohen YI, Rappaport ZH, Freidkin I, Albeck M, Longo DL, et al. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Research. 64: 1843-52. PMID 14996748 DOI: 10.1158/0008-5472.Can-03-3179  0.393
2004 Sredni B, Gal R, Cohen IJ, Dazard JE, Givol D, Gafter U, Motro B, Eliyahu S, Albeck M, Lander HM, Kalechman Y. Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 400-2. PMID 14656992 DOI: 10.1096/Fj.03-0552Fje  0.328
2003 Makarovsky D, Kalechman Y, Sonino T, Freidkin I, Teitz S, Albeck M, Weil M, Geffen‐Aricha R, Yadid G, Sredni B. Tellurium Compound AS101 Induces PC12 Differentiation and Rescues the Neurons from Apoptotic Death Annals of the New York Academy of Sciences. 1010: 659-666. PMID 15033807 DOI: 10.1196/Annals.1299.120  0.305
2003 Gafter-Gvili A, Sredni B, Gal R, Gafter U, Kalechman Y. Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. American Journal of Physiology. Cell Physiology. 284: C1593-603. PMID 12734112 DOI: 10.1152/Ajpcell.00537.2002  0.345
2003 Kalechman Y, Sredni B, Weinstein T, Freidkin I, Tobar A, Albeck M, Gafter U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. Journal of the American Society of Nephrology : Jasn. 14: 620-30. PMID 12595497 DOI: 10.1097/01.Asn.0000053415.29636.4F  0.396
2002 Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. Journal of Immunology (Baltimore, Md. : 1950). 169: 384-92. PMID 12077268 DOI: 10.4049/Jimmunol.169.1.384  0.39
2001 Dagon Y, Dovrat S, Vilchik S, Hacohen D, Shlomo G, Sredni B, Salzberg S, Nir U. Double-stranded RNA-dependent protein kinase, PKR, down-regulates CDC2/cyclin B1 and induces apoptosis in non-transformed but not in v-mos transformed cells. Oncogene. 20: 8045-8056. PMID 11781817 DOI: 10.1038/Sj.Onc.1204945  0.325
2000 Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B. Synergistic anti‐tumoral effect of paclitaxel (taxol)+AS101 in a murine model of B16 melanoma: Association with ras‐dependent signal‐transduction pathways International Journal of Cancer. 86: 281-288. PMID 10738258 DOI: 10.1002/(Sici)1097-0215(20000415)86:2<281::Aid-Ijc20>3.0.Co;2-X  0.368
2000 Sredni B, Longo DL, Catane R, Shani A, Albeck M, Kalechman Y. Synergistic antitumoral effect of the immunomodulator AS101 + paclitaxel (Taxol) Experimental Hematology. 28: 1496. DOI: 10.1016/S0301-472X(00)00630-5  0.372
1998 Rosenblatt-Bin H, Kalechman Y, Vonsover A, Xu RH, Da JP, Shalit F, Huberman M, Klein A, Strassmann G, Albeck M, Sredni B. The immunomodulator AS101 restores T(H1) type of response suppressed by Babesia rodhaini in BALB/c mice. Cellular Immunology. 184: 12-25. PMID 9626331 DOI: 10.1006/Cimm.1998.1251  0.365
1998 Shalit F, Sredni B, Rosenblatt-Bin H, Kazimirsky G, Brodie C, Huberman M. Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures. Neuroreport. 8: 3577-80. PMID 9427329 DOI: 10.1097/00001756-199711100-00031  0.555
1997 Gafter U, Sredni B, Segal J, Kalechman Y. Suppressed cell-mediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion Journal of Clinical Immunology. 17: 408-419. PMID 9327341 DOI: 10.1023/A:1027372409361  0.411
1997 Gafter U, Sredni B, Segal J, Kalechman Y. Immunization with WBC suppresses T cells and NK activity in vitro. Transplantation Proceedings. 29: 2703-2705. PMID 9290797 DOI: 10.1016/S0041-1345(97)00563-0  0.331
1997 Gafter U, Sredni B, Segal J, Kalechman Y. Immunization with WBC induces monocyte suppression activity in vitro Transplantation Proceedings. 29: 2649-2650. PMID 9290776 DOI: 10.1016/S0041-1345(97)00542-3  0.31
1996 Xu R, Kalechman Y, Albeck M, Kung H, Sredni B. Inhibition of B16 melanoma metastasis by the immunomodulator AS101. International Journal of Oncology. 9: 319-325. PMID 21541518 DOI: 10.3892/Ijo.9.2.319  0.381
1996 Rosenblatt-Bin H, Klein A, Sredni B. Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxide Parasite Immunology. 18: 297-306. PMID 9229382 DOI: 10.1046/J.1365-3024.1996.D01-104.X  0.331
1996 Gafter U, Kalechman Y, Sredni B. Blood Transfusion Enhances Production of T-Helper-2 Cytokines and Transforming Growth Factor β in Humans Clinical Science. 91: 519-523. PMID 8983880 DOI: 10.1042/Cs0910519  0.338
1996 Herman S, Kalechman Y, Gafter U, Sredni B, Malik Z. Photofrin II induces cytokine secretion by mouse spleen cells and human peripheral mononuclear cells Immunopharmacology. 31: 195-204. PMID 8861745 DOI: 10.1016/0162-3109(95)00047-X  0.38
1996 Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Tincani A, Dicker D, Shoenfeld Y. Aspirin‐Interleukin‐3 Interrelationships in Patients With Anti‐Phospholipid Syndrome American Journal of Reproductive Immunology. 35: 80-84. PMID 8839134 DOI: 10.1111/J.1600-0897.1996.Tb00011.X  0.361
1996 Sredni B, Tichler T, Shani A, Catane R, Kaufman B, Strassmann G, Albeck M, Kalechman Y. Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS 101 Journal of the National Cancer Institute. 88: 1276-1284. PMID 8797767 DOI: 10.1093/Jnci/88.18.1276  0.41
1996 Djaldetti M, Sredni B, Zigelman R, Verber M, Fishman P. Muscle cells produce a low molecular weight factor with anti-cancer activity Clinical & Experimental Metastasis. 14: 189-196. PMID 8674272 DOI: 10.1007/Bf00053891  0.34
1996 Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A, Tichler T, Shapira J, Bruderman I, Catane R, Kaufman B, Whisnant JK, Mettinger KL, Kalechman Y. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models International Journal of Cancer. 65: 97-103. PMID 8543404 DOI: 10.1002/(Sici)1097-0215(19960103)65:1<97::Aid-Ijc17>3.0.Co;2-F  0.367
1995 Huberman M, Sredni B, Stern L, Kott E, Shalit F. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease Journal of the Neurological Sciences. 130: 161-164. PMID 8586980 DOI: 10.1016/0022-510X(95)00016-U  0.336
1995 Shalit F, Sredni B, Brodie C, Kott E, Huberman M. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clinical Immunology and Immunopathology. 75: 246-50. PMID 7768042 DOI: 10.1006/Clin.1995.1078  0.531
1995 Kalechman Y, Shani A, Albeck M, Sredni B. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties Immunopharmacology. 29: 149-158. PMID 7539780 DOI: 10.1016/0162-3109(94)00054-J  0.363
1995 Kalechman Y, Zuloff A, Albeck M, Strassmann G, Sredni B. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate Blood. 85: 1555-1561. DOI: 10.1182/Blood.V85.6.1555.Bloodjournal8561555  0.392
1995 Huberman M, Shalit F, Roth-Deri I, Gutman B, Sredni B, Kott E. Decreased IL-3 production by peripheral blood mononuclear cells in patients with M.S. Journal of Neuroimmunology. 38-38. DOI: 10.1016/0165-5728(95)98979-L  0.348
1994 Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, Kott E, Sredni B. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. Journal of Neuroimmunology. 52: 147-152. PMID 8034754 DOI: 10.1016/0165-5728(94)90108-2  0.591
1994 Shalit F, Sredni B, Stern L, Kott E, Huberman M. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients ☆ Neuroscience Letters. 174: 130-132. PMID 7970167 DOI: 10.1016/0304-3940(94)90003-5  0.355
1994 Sredni B, Rosenthal-Galili Z, Michlin H, Sobelman D, Seger Y, Blagerman S, Kalechman Y, Rager-Zisman B. Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101. Immunology Letters. 43: 159-65. PMID 7721328 DOI: 10.1016/0165-2478(94)90217-8  0.378
1993 Huberman M, Shalit F, Roth-Deri I, Gutman B, Kott E, Sredni B. Decreased IL-3 production by peripheral blood mononuclear cells in patients with multiple sclerosis Journal of the Neurological Sciences. 118: 79-82. PMID 8229053 DOI: 10.1016/0022-510X(93)90249-X  0.37
1993 Kalechman Y, Herman S, Gafter U, Sredni B. Enhancing effects of autologous erythrocytes on human or mouse cytokine secretion and IL-2R expression. Cellular Immunology. 148: 114-129. PMID 8098664 DOI: 10.1006/Cimm.1993.1095  0.418
1993 Kalechman Y, Shani A, Albeck M, Barkai IS, Sredni B. Increased DNA repair ability after irradiation following treatment with the immunomodulator AS101. Radiation Research. 136: 197-204. DOI: 10.2307/3578611  0.308
1993 Gafter U, Kalechman Y, Zevin D, Korzets A, Livni E, Klein T, Sredni B, Levi J. Tubulointerstitial nephritis and uveitis: association with suppressed cellular immunity Nephrology Dialysis Transplantation. 8: 821-826. DOI: 10.1093/Ndt/8.9.821  0.364
1992 Kalechman Y, Albeck M, Sredni B. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin. Cellular Immunology. 143: 143-153. PMID 1623562 DOI: 10.1016/0008-8749(92)90012-E  0.323
1992 Gafter U, Kalechman Y, Sredni B. Induction of a subpopulation of suppressor cells by a single blood transfusion. Kidney International. 41: 143-148. PMID 1534385 DOI: 10.1038/Ki.1992.19  0.371
1992 Fishman P, Sredni B, Reznik R, Hart J, Ziegelman R, Djaldetti M. Cultured human cord blood cells spontaneously produce a factor with basophil-promoting activity. Immunology Letters. 34: 189-193. PMID 1283154 DOI: 10.1016/0165-2478(92)90212-7  0.34
1991 Fishman P, Sredni B, Djaldetti M. The relationship between interleukin-3-like activity and basophil production in chronic myeloid leukemia patients Immunology Letters. 28: 73-77. PMID 2071173 DOI: 10.1016/0165-2478(91)90129-X  0.38
1991 Kalechman Y, Michlin H, Gafter U, Sredni B. Generation of T cell lines with suppressive activity derived from autorosette-forming cells of patients with autoimmune diseases. Annals of the New York Academy of Sciences. 628: 373-378. PMID 1829876 DOI: 10.1111/J.1749-6632.1991.Tb17272.X  0.4
1991 Gutman B, Huberman M, Shalit F, Roth-Deri I, Sredni B, Kott E. Secretion of cytokines from blood mononuclear cells (MNC) in Alzheimer's disease Journal of Neuroimmunology. 35: 80. DOI: 10.1016/0165-5728(91)90986-H  0.31
1990 Kalechman Y, Gafter U, Sobelman D, Sredni B. The effect of a single whole-blood transfusion on cytokine secretion. Journal of Clinical Immunology. 10: 99-105. PMID 2110941 DOI: 10.1007/Bf00918191  0.323
1990 Djaldetti R, Fishman P, Shtatlender V, Sredni B, Djaldetti M. Effect of dexamethasone on IL-1 and IL-3-LA release by unstimulated human mononuclear cells Biomedicine & Pharmacotherapy. 44: 515-518. PMID 2085666 DOI: 10.1016/0753-3322(90)90172-6  0.374
1988 Eisenstein Z, Engelsman E, Weiss M, Kalechman Y, Sredni B. Production of and response to interleukin-2 in Graves' disease. Journal of Clinical Immunology. 8: 349-355. PMID 2972741 DOI: 10.1007/Bf00917150  0.326
1987 Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, BenYa'akov M, Tamari T, Shalit F, Albeck M. A new immunomodulating compound (AS-101) with potential therapeutic application Nature. 330: 173-176. PMID 3118216 DOI: 10.1038/330173A0  0.431
1984 Kedar E, Ikejiri BL, Timonen T, Bonnard GD, Reid J, Navarro NJ, Sredni B, Herberman RB. Antitumor Reactivity In Vitro and In Vivo of Lymphocytes from Normal Donors and Cancer Patients Propagated in Culture with T Cell Growth Factor (TCGF) The Journal of Urology. 131: 183-183. DOI: 10.1016/S0022-5347(17)50272-4  0.333
1983 Kedar E, Ikejiri BL, Timonen T, Bonnard GD, Reid J, Navarro NJ, Sredni B, Herberman RB. Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF). European Journal of Cancer & Clinical Oncology. 19: 757-73. PMID 6603361 DOI: 10.1016/0277-5379(83)90009-3  0.365
1982 Kedar E, Ikejiri BL, Sredni B, Bonavida B, Herberman RB. Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cellular Immunology. 69: 305-29. PMID 6980720 DOI: 10.1016/0008-8749(82)90075-2  0.367
1982 Sredni B, Sieckmann DG, Kumagai S, House S, Green I, Paul WE. Long-term culture and cloning of nontransformed human B lymphocytes. The Journal of Experimental Medicine. 154: 1500-16. PMID 6975349 DOI: 10.1084/Jem.154.5.1500  0.31
1981 Gorelik E, Kedar E, Sredni B, Herberman R. In vivo anti‐tumor effects of local adoptive transfer of mouse and human cultured lymphoid cells International Journal of Cancer. 28: 157-164. PMID 6976330 DOI: 10.1002/Ijc.2910280208  0.365
1981 Sredni B, Volkman D, Schwartz RH, Fauci AS. Antigen-specific human T-cell clones: development of clones requiring HLA-DR-compatible presenting cells for stimulation in presence of antigen Proceedings of the National Academy of Sciences of the United States of America. 78: 1858-1862. PMID 6972044 DOI: 10.1073/Pnas.78.3.1858  0.329
1981 Sredni B, Matis LA, Lerner EA, Paul WE, Schwartz RH. Antigen-specific T cell clones restricted to unique F1 major histocompatibility complex determinants. Inhibition of proliferation with monoclonal anti-Ia antibody. The Journal of Experimental Medicine. 153: 677-93. PMID 6166704 DOI: 10.1084/Jem.153.3.677  0.31
1980 Sredni B, Schwartz RH. Alloreactivity of an antigen-specific T-cell clone Nature. 287: 855-857. PMID 6968869 DOI: 10.1038/287855A0  0.335
1980 Sredni B, Tse HY, Schwartz RH. Direct cloning and extended culture of antigen-specific MHC-restricted, proliferating T lymphocytes [17] Nature. 283: 581-583. PMID 6153457 DOI: 10.1038/283581A0  0.307
1978 Sredni B, Michlin H, Kalechman Y, Rozenszajn LA. Regulatory effects of macrophage-secreted factors on T-lymphocyte colony growth Cellular Immunology. 36: 15-27. PMID 305288 DOI: 10.1016/0008-8749(78)90246-0  0.321
1976 Sredni B, Kalechman Y, Michlin H, Rozenszajn LA. Development of colonies in vitro of mitogen-stimulated mouse T lymphocytes. Nature. 259: 130-132. PMID 1082102 DOI: 10.1038/259130A0  0.311
Show low-probability matches.